News | August 08, 2022
Valiant Organics to start production of OAP and Pharma Intermediates
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The WAVEsystem with the WAVEcontrol 4.0 embedded
Sandu Kumarvin is an Ayurvedic digestive and immunity booster for children and also offers several other benefits.
The total budget of Rs. 3119.46 crores has been allocated/ released as a central share to States/UTs since the inception of the scheme and they have reported an expenditure of Rs. 2290.20 crores.
Subscribe To Our Newsletter & Stay Updated
